^
    5d
    Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG) (clinicaltrials.gov)
    P2, N=61, Not yet recruiting, First People's Hospital of Hangzhou
    New P2 trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    6d
    Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1)
    |
    FLT3-ITD mutation • NPM1 mutation
    |
    Venclexta (venetoclax) • azacitidine • decitabine • Synribo (omacetaxine mepesuccinate)
    12d
    RRx-001 inhibits G6PD to deplete NADPH and trigger disulfidptosis coupled with DAMP-mediated immunogenic cell death in hepatocellular carcinoma. (PubMed, Cell Death Discov)
    In vivo, RRx-001 significantly inhibits tumor growth, enhances T-cell infiltration, promotes M1 macrophage polarization, downregulates PD-L1 expression, and strengthens anti-tumor immunity through T cell-related pathways. With both metabolic and immunomodulatory effects, RRx-001 provides a basis for novel HCC therapies, and future research could explore its synergistic effects with immune checkpoint inhibitors.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • HMGB1 (High Mobility Group Box 1) • G6PD (Glucose-6-Phosphate Dehydrogenase)
    |
    PD-L1 expression
    |
    nibrozetone (RRx-001)
    15d
    OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1, N=12, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    OMO-103
    22d
    VEN-OM: Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=6, Completed, University of Illinois at Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    Venclexta (venetoclax) • Synribo (omacetaxine mepesuccinate)
    22d
    Efficacy and safety of venetoclax-cytarabine-homoharringtonine-based cytoreductive therapy before allogeneic hematopoietic stem cell transplantation in refractory/relapsed acute myeloid leukemia with RUNX1::RUNX1T1: a retrospective study (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    All patients remained disease-free, with no events of measurable residual disease (MRD) positivity by flow cytometry or molecular analysis documented. These findings preliminarily confirm that venetoclax, cytarabine, and homoharringtonine-based cytoreductive therapy is a safe and effective bridging therapy for allo-HSCT in patients with refractory/relapsed AML and RUNX1::RUNX1T1 fusion gene.
    Retrospective data • Journal
    |
    RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)
    |
    RUNX1-RUNX1T1 fusion
    |
    Venclexta (venetoclax) • cytarabine • Synribo (omacetaxine mepesuccinate)
    25d
    Homoharringtonine inhibits growth and migration in non-small cell lung cancer via PDIA4-mediated modulation of autophagy and EMT. (PubMed, Arch Pharm Res)
    Additionally, HHT inhibits NSCLC migration by modulating epithelial-mesenchymal transition (EMT) signaling. These findings highlight PDIA4 as a critical mediator of HHT efficacy against NSCLC, provide novel insights into PDIA4-associated therapy, and support the translational potential of HHT in NSCLC treatment.
    Journal
    |
    PDIA4 (Protein Disulfide Isomerase Family A Member 4)
    |
    Synribo (omacetaxine mepesuccinate)
    25d
    VAH vs VA in Newly Diagnosed Elderly AML (clinicaltrials.gov)
    P3, N=308, Not yet recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
    New P3 trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    1m
    Homoharringtonine and Gilteritinib Synergistically Induce Apoptosis and Suppress Viability in FLT3-ITD-Positive AML Cells. (PubMed, Biomedicines)
    The combination enhanced the p53 expression. Our findings elucidate the mechanism underlying this synergistic interaction and underscore the potential of p53 status as a predictive biomarker for identifying patients most likely to benefit from HHT and gilteritinib combination therapy.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3) • HSPA8 (Heat Shock Protein Family A (Hsp70) Member 8)
    |
    TP53 mutation • FLT3-ITD mutation • TP53 wild-type
    |
    Xospata (gilteritinib) • Synribo (omacetaxine mepesuccinate)
    2ms
    Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma (clinicaltrials.gov)
    P1/2, N=40, Not yet recruiting, National Institute of Neurological Disorders and Stroke (NINDS)
    New P1/2 trial
    |
    IDH wild-type
    |
    LMP744
    2ms
    A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. (PubMed, Cell Rep Med)
    In luminal cells, EIF1A knockdown and the translation inhibitor homoharringtonine (HHT) both suppress HIF-1α translation and tumor growth, while promoting infiltration of anticancer immune cells including PD-1- T cells and CD163- macrophages...Collectively, this work defines conserved molecular features across PCa subtypes, providing promising insights for clinical management. This study was registered at Clinicaltrials.gov (NCT06834321).
    Journal
    |
    PD-1 (Programmed cell death 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CD163 (CD163 Molecule) • EIF1AX (Eukaryotic Translation Initiation Factor 1A X-Linked)
    |
    Synribo (omacetaxine mepesuccinate)
    2ms
    IDP-121-2 MYCrocytic: Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic) (2025-521902-17-00)
    P1/2, N=60, Not yet recruiting, Idp Discovery Pharma S.L.
    New P1/2 trial
    |
    IDP-121